BDBM300035 2-(benzyloxy)-N- [(2R)-1- hydroxypropan-2- yl]-6-[4-(4- methoxy-1H- pyrazolo[3,4- b]pyridin-3- yl)piperidin-1- yl]pyrimidine-4- carboxamide::US9593097, Example 415
SMILES: COc1ccnc2[nH]nc(C3CCN(CC3)c3cc(nc(OCc4ccccc4)n3)C(=O)N[C@H](C)CO)c12
InChI Key:
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase receptor UFO (Homo sapiens (Human)) | BDBM300035 (2-(benzyloxy)-N- [(2R)-1- hydroxypropan-2- yl]-6-[...) | PDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | <0.0130 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description AXL enzyme inhibition (% inhibition, Kiapp and Ki values) by small molecule inhibitors was evaluated using a fluorescence-based microfluidic mobility... | US Patent US9593097 (2017) BindingDB Entry DOI: 10.7270/Q2GM89BD | |||||||||||
More data for this Ligand-Target Pair |